We integrate research into the biology of life across a magnitude of scales, from single molecules through to whole organisms. Using cutting-edge and world-leading multi-omics technologies, our research answers impactful biological questions.
A key focus of our research is on delivering novel therapeutics with reduced toxicity to patients via an improved understanding of biological mechanisms.
Our work spans the atomic structure of molecules, signalling cellular pathways and the detection of abnormal cellular phenotypes.
Download the ISMIB Research Brochure (PDF, 7.5MB) or ISMIB Researcher Directory (PDF, 5.2MB).
We're bringing together biochemistry, cutting-edge technology and multi-omics approaches to study the chemistry of life. From proteins to complex biological systems, we provide vital links between both basic and translational research.
Bridging discovery science with therapeutic applications in cancer patients. Our mission is to optimise effective collaborations between scientists and clinicians to find better ways to detect and treat cancer.
Our internationally excellent, multidisciplinary research spans life, physical and clinical sciences, focused on investigating mechanisms of drug efficacy and toxicity. Our aim is to develop new and improve existing therapies for the benefit of patients.
CELT Global Health aims to broaden understanding of long-acting medicines, create new interventions and accelerate the research and development of new therapies.
Improving health and wellbeing by optimising the use of existing drugs and accelerating the development of new treatments. Through clinical trials and experimental medicine, TherEx delivers significant health impact in therapeutics.
CERSI-PGx is dedicated to accelerating the safe and effective use of pharmacogenomics in healthcare.
Combining internationally recognised clinical and research strengths to deliver research-led improvements in the quality and safety of patient care.
We're researching the newest next-generation drugs, actual biological structures themselves that bind to and stimulate the immune system. These drugs will be used to treat patients with more advanced, malignant cancers.
Together with our NHS supraregional referral centre for eye cancer, we have spearheaded the development and implementation of prognostic tests to predict metastasis likelihood in individual patients.
Human papillomavirus (HPV) is linked to 5% of all cancers worldwide. Since 2008 girls in the UK received HPV vaccination to reduce the incidence of cervical cancer. Research carried out in Liverpool provided evidence that HPV is also linked to a high incidence in head and neck cancer.
Liverpool Shared Research Facilities offer flexible access to world-class equipment and expertise through its Shared Research Facilities.
The Human Liver Research Facility enables wider access to human liver materials for research purposes in a collaboration between academic staff and the Hepatobiliary Unit at Liverpool University Hospitals NHS Foundation Trust (LUHFT).
Our local and global partnerships provide vital support to our research activity.
